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Open access under CC BThe aim of this study was to investigate whether supplemental IGF-1Ea transgene expression induces
activation of local cardiac and bone marrow stem cell population to mediate mammalian heart repair.
In physiologic conditions, cardiac overexpression of the IGF-1Ea propeptide is associated with an enrich-
ment of c-Kit/Sca-1 positive side population cells in the bone marrow and the occurrence of an endothe-
lial-primed CD34 positive side population in the heart. This cellular proﬁle is shown here to correlate
with the expression of cytokines involved in stem cell mobilization and vessel formation. This molecular
and cellular interplay favored IGF-1Ea-mediated vessel formation in injured hearts. The physiologic and
pathologic connection between cytokines and stem cells in response to IGF-1Ea may represent an impor-
tant model to understand how to elicit endogenous reparative signaling.
 2011 Elsevier Inc. Open access under CC BY-NC-ND license.1. Introduction
An emerging concept is that the mammalian myocardium has
the potential to regenerate, but that regeneration might be inefﬁ-
cient to repair the extensive damage caused by myocardial infarct
(MI). Stem cell transplantation, as well as delivery of synthetic
biomaterial, represents a promising approach to elicit myocardial
regeneration, although their efﬁcacy and efﬁciency is still under
debate. An alternative to stem cell transplantation is the retrieving
of the initial healing capacity of the heart by promoting endoge-
nous stem cells homing. Interventions towards this direction have
to promote translocation of stem cells from the site of storage to
the infarct, their activation and differentiation into myocytes and
coronary vessels. Several growth factors and cytokines have been
shown to elicit stem cell mobilization from bone marrow or
peripheral blood [1], as well as activation of a cardiac resident stem
cell pool [2,3].
In our laboratory, the regenerative properties of the IGF-1Ea
propeptide and its dramatic promotion of cell survival and renewal
in cardiac and skeletal muscle have been extensively documented,
making it an attractive candidate for possible enhancement of cell-
based regenerative therapies in injured post-mitotic organs. It hastre, National Heart and Lung
6JH Hareﬁeld, UK
tini).
Y-NC-ND license.been previously shown that skeletal muscle-restricted expression
of IGF-1Ea increased bone marrow and local stem cell pools, pro-
viding a mechanistic explanation for its dramatic effects on muscle
mass and integrity in vivo [4]. We recently demonstrated that the
IGF-1Ea propeptide, expressed in transgenic mouse muscle under
cardiac-speciﬁc post-mitotic control, induces cardiac recovery with
decreased scar formation and lowered inﬂammatory response fol-
lowing myocardial infarction [5]. These studies demonstrate that
supplementary IGF-1Ea expression is an effective and potentially
powerful approach to counter a number of prevalent and life-
threatening cardiovascular and muscular pathologies by eliciting
the activity of endogenous cells and molecules for repairing the in-
jured tissues.
In this study, we investigated whether cardiac overexpression
of IGF-1Ea propetide modulates local and distal stem cell popula-
tions in physiologic and pathologic conditions. Side population
cells in the heart have been previously characterized to be a stem
cell population capable of differentiating into different lineages
including hematopoietic, muscle and endothelial cell lineages
[6,7]. By the analysis of the side population, we observed that
IGF-1Ea promotes cellular and molecular cross-talk between the
heart and the bone marrow by the release of speciﬁc cytokines
involved in activating bone marrow c-Kit/Sca-1 positive cells and
preferentially selecting a local cardiac population of hematopoi-
etic- and endothelial-lineage cells. Furthermore, the signaling
mediated by IGF-1Ea enriches the heart of new capillaries in
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cular function previously described [5]. Understanding the inter-
play between cardiac and bone marrow cells mediated by IGF-
1Ea in physiologic conditions may be important to stimulate
endogenous mediators of cardiovascular repair in a clinical setting.2. Materials and methods
An expanded Materials and Methods section can be found in the
online supplement.
2.1. Animals
FVB wild-type (WT) and IGF-1Ea transgenic (TG) mice were
housed in a temperature-controlled (22 C) room with a 12:12 h
light–dark cycle. All procedures were performed in compliance
with International and National (UK Home Ofﬁce) regulations. Car-
diac-speciﬁc Alpha-Myosin Heavy Chain (MHC)/IGF-1Ea mice were
generated as previously described [5].
2.2. Isolectin-B4 staining
Mice were anesthetized before cervical dislocation, and hearts
were perfused with 4% paraformaldehyde (PFA), then excised and
embedded in parafﬁn. Isolectin-B4 staining was performed as pre-
viously described [8]. Capillaries were counted in an area of
500 lm2 as assessed by the program Imaging Software NIS-Ele-
ments AR 3.0. Three hearts for group were analyzed and 10 sec-
tions were measured for each group. Images were captured byFig. 1. Characterization of bone marrow side population and cytokine proﬁle in WT and
cells in WT (B-D) and TG (A-C) mice. Percentage of cells in each region is shown below th
markers in three independent experiments. Asterisk (⁄) indicates signiﬁcant increase of c
A (G), SDF-1 (H) and G-CSF (I) in 4 month old WT and TG hearts. Normalization was pe
p < 0.05, whereas ⁄⁄⁄ show values with p < 0.001, (WT n = 8; TG n = 5). No signiﬁcant, nZeiss Axioskop microscope connected to a Nikon digital camera
DXM1200F.
2.3. Cardiac injury
3–4 month-old WT and TG mice were anesthetized by isoﬂu-
rane inhalation and 25 lL of cardiotoxin (CTX) 10 mmol/L (Lato-
xan) were injected in the left ventricle wall as previously
described [5].
2.4. Statistical analysis
Statistical analyses were performed using GraphPad Prism 4. All
measurements are reported as values ± standard deviation. A sig-
niﬁcant difference was considered when p < 0.05 and was marked
as (⁄) and (⁄⁄⁄) for p < 0.001.3. Results
3.1. IGF-1Ea modulates the amount of c-Kit/Sca-1 positive bone
marrow cells and regulates the expression of speciﬁc cytokines in
physiologic conditions
To evaluate whether cardiac overexpression of IGF-1Ea affected
bone marrow stem cell population, we investigated the side
population (SP) cells by ﬂow cytometric analysis (Fig. 1 and Sup-
plementary Figure 1). Bone marrow side population (BM–SP) was
identiﬁed in both wild-type (WT) and IGF-1Ea transgenic (TG) mice
(Supplementary Figure 1) and its appearance was blocked by theTG mice. Expression of c-Kit (A-D), Sca-1 (A-B) and CD45 (C-D) in bone marrow SP
e graphs. (E) Percentage of BM-SP cells expressing both Sca-1 and c-Kit cell surface
ells in TG bone marrow compared to WT (p < 0.05). Real time PCR of MCP2 (F), VEGF-
rformed relative to values obtained by 18S rRNA. Asterisk (⁄) indicates values with
s. Values are represented as Mean +/SEM.
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ure 1C). In agreement with previous analyses [9,10], we observed
that side population consisted of CD45-, c-Kit- and Sca-1- positive
cells (Fig. 1A, B, C and D). Interestingly, transgenic animals pre-
sented a signiﬁcant increased number of cells positive for both sur-
face markers c-Kit and Sca-1 (Region 6 of Fig. 1A, B and E), whereas
the amount of c-Kit/CD45 positive cells remained invariant (Region
6 of Fig. 1C and D). Modulation of cell populations in the bone mar-
row is favored by injection of speciﬁc cytokines [11], such as VEGF-
A [12,13], SDF-1 [14] and G-CSF [15]. Intriguingly, the monocyte
chemoattractant proteins, known to regulate monocytes recruit-
ment from the bone marrow to the site of injury [16], have been
shown to increase c-Kit/Sca-1 positive hematopoietic stem cells
(HSCs) in the peritoneal cavity [17] and mobilize mesenchymal
stem cells (MSC) from the bone marrow [18]. In order to correlate
the modulation of bone marrow cells with cardiac signaling, tran-
script levels of VEGF-A, SDF1, G-CSF and MCP2 were analyzed in
WT and TG hearts. In physiologic conditions, the expression of
SDF-1 (Fig. 1H) and G-CSF (Fig. 1I) remained comparable between
WT and TG hearts. We previously shown that MCP1 expression is
not affected by IGF-1Ea overexpression [5]. Interestingly, MCP2
transcript is signiﬁcantly upregulated in TG hearts compared to
WT hearts (Fig. 1F). In parallel, IGF-1Ea overexpression was associ-
ated with increased expression of VEGF-A (Fig. 1G) compared to
WT hearts.
Taken together, these data shows a differential cytokine proﬁle
in transgenic hearts in physiologic conditions and suggests a corre-
lation between the bone marrow cellular proﬁle and the expres-
sion of MCP2 and VEGF-A in the heart of transgenic animals.Fig. 2. Identiﬁcation of cell surface markers in cardiac SP of WT and TG hearts. Panels repr
The proﬁles showed were reproducible in three independent experiments. Percentage o3.2. Local cardiac SP is primed to form endothelial progenitor cell-like
colonies by overexpression of the IGF-1Ea propeptide
To analyze whether cardiac IGF-1Ea overexpression affected the
local cardiac stem cell population, Hoechst analysis of WT and TG
SP was performed in physiologic conditions (Fig. 2 and Supplemen-
tary Figure 2). The data show that both WT and TG post-natal
hearts presented an undistinguishable cardiac SP (Supplementary
Figure 2A and B), which is sensitive to verapamil treatment (Sup-
plementary Figure 2C). Interestingly, most of the cells were nega-
tive for c-Kit, Sca-1 and CD45 in both WT (Fig. 2A) and TG
(Fig. 2B) SP. The majority of cells were positive for the endothelial
and hematopoietic lineage-speciﬁc marker CD34 (Fig. 2A and B). A
small population of cardiac SP cells was positive for both CD34/
CD71 (2.83%) and CD34/Flk1 (1.79%) in TG hearts (Fig. 2B, regions
5 of ﬁrst and second panel), whereas CD34/Flk1 (1.89%) cells were
present in WT hearts (Fig. 2A, region 5 of second panel). Although
enzymatic treatment used to dissociate the cells from cardiac tis-
sue may have affected integrity of speciﬁc cell surface proteins,
the presence of cells positive for CD45 (Regions R2 and R6 in Sup-
plementary Figure 2D, E, F, and G), Sca-1 (Regions R5 in Supple-
mentary Figure 2D and E) and to a lower extent c-Kit (Regions 9
in Supplementary Figure 2F and G) in the collagenase-treated main
population (MP) of both WT and TG hearts indicates that in our
conditions cardiac SP cells are not positive for the above cell sur-
face markers.
To investigate whether the CD34 positive cells retained multi-
potent differentiation potential, FACS-sorted cells were plated in
culture conditions favoring colony-forming unit of granulocytes,esent CD71, CD34, CD45, Sca-1 and c-Kit expression inWT (A) and TG (B) cardiac SP.
f cells in the regions is reported below each panel.
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(Fig. 3A). Cells sorted from both WT and TG hearts were capable
of differentiating into cells of hematopoietic/myeloid lineage as
shown in Fig. 3A, indicating that IGF-1Ea overexpression did not af-
fect hematopoietic differentiation program compared to WT SP
cells.
To further investigate whether the presence of IGF-1Ea change
the cellular response to different growth factors, we analyzed the
responsiveness of CD34 positive WT and TG cells to a combination
of EGF and PDGF-BB factors and to serum, shown previously to fa-
vor proliferation of multipotent bone marrow-derived stem cells
[19]. CD34 positive cells presented a cobblestone-like morphology
that was maintained during all the experimental procedures
(Fig. 3B). Supplementation of EGF and PDGF-BB in the culture med-
ia increased cell number in both WT and TG cells (Fig. 3C). In pres-
ence of ﬁbroblasts (Fig. 3D), CD34 positive cells increased in size,
indicating responsiveness to the cell feeder layer. When cells were
plated in 5% horse serum (HS) without supplementation of addi-
tional growth factors (Fig. 3E), we observed a differential response
between WT and TG CD34 positive SP cells. WT cells retained their
morphological structure but did not proliferate in these conditions,Fig. 3. Differentiation potential of WT and TG SP cells and IGF-1Ea-mediated vessel forma
GF M3434 for CFU-GEMM assessment. (B) WT and TG CD34 positive cells from SP were s
Cells proliferate after 1 week (C) and presented increased cell size when plate on ﬁbrobl
with DMEM containing 5% HS. WT cells (upper panel) maintained a cobblestone-like mor
with cells at the edge forming tubular-like structures (white arrows). (F) Capillary de
Section 2. The values reported are the average of three independent experiments per g
between WT and TG in the distal zone (p > 0.05), whereas signiﬁcant increase is observed
Mean +/Standard Deviation.indicating their requirement for EGF and PDGF for cell division
(Fig. 3E). Intriguingly, TG CD34 positive SP cells displayed charac-
teristic of early growth endothelial progenitor cells (EPCs) [20]
(Fig. 3E, right panel, black arrow) and formed tubular-like struc-
tures at the edge of the central colony (Fig. 3E, right panel, white
arrows).
These data indicate that overexpression of IGF-1Ea can prime
CD34 positive SP cells to differentiate spontaneously into endothe-
lial-like cells in presence of serum.3.3. IGF-1Ea induces vessel formation in vivo after myocardial infarct
but not in physiologic conditions
Experiments in vitro showed a differential responsiveness of the
SP to serum treatment when exposed to an IGF-1Ea-enriched
environment. These data suggest that IGF-1Ea may induce the
activation of a population of stem cells capable of producing new
vessels. Nevertheless, four month old WT and TG hearts showed
a comparable number of capillaries in physiologic conditions
(Supplementary Figure 3A).tion. (A) WT and TG CD34 positive cells from SP were sorted and plated in Methocult
orted and plated on matrigel-coated dishes in presence of EGF, PDGF-BB and 2% FCS.
asts (D). (E) WT and TG SP cells were plated on matrigel-coated dishes and treated
phology, while TG cells (lower panel) are organized in a central colony (black arrow)
nsity was measured after staining with biotinylated Isolectin-B4 as described in
roup. Student’s t-test shows no signiﬁcant (ns) difference in the capillary density
in TG hearts in the area bordering the infarct (⁄, p < 0.05). Values are represented as
Fig. 4. Cytokines’ proﬁle in WT and TG hearts after cardiotoxin injection. MCP2 (A), VEGF-A (B), SDF-1 (C) and G-CSF (D) transcripts were analyzed by RT-PCR in WT and TG
hearts 1 month after cardiotoxin injection. Normalization was performed relative to values obtained by 18S rRNA. Asterisk (⁄) indicates values with p < 0.05 (WT n = 3; TG
n = 4). No signiﬁcant (ns). Values are represented as Mean +/SEM. (E) Mechanism of IGF-1Ea-mediated heart and bone marrow cross-talk in cardiac repair. Cardiac
overexpression of the propetide IGF-1Ea induces upregulation of VEGF-A and MCP2 (1) leading to modulation of bone marrow SP cells (2) that can proliferate and/or migrates
into the heart (3) to possibly contribute to vessel formation upon myocardial injury (4).
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cardial injury, capillaries were quantiﬁed 1 month after cardiotox-
in (CTX) injection (Fig. 3F and Supplementary Figure 3B).
Interestingly, IGF-1Ea induced increased capillary density in the
area bordering the injured site (Fig. 3F, lower panel) but not in
the remote zone (Fig. 3F, upper panel). Parallel to vessel formation,
IGF-1Ea overexpression increased the levels of VEGF-A transcript
compared to WT hearts (Fig. 4B), whereas MCP2 (Fig. 4A), SDF-1
(Fig. 4C) and G-CSF (Fig. 4D) expression was not regulated by trans-
gene overexpression in response to injury.
These data show that the propeptide IGF-1Ea elicits vessel for-
mation only in response to injury.4. Discussion
Cytokine release beneﬁts the injured heart through direct
effects in the myocardium and indirectly by mobilization of pro-
genitor cells. Indeed, it has been reported that neovascularization
of human ischemic tissues after VEGF165 treatment is not limited
to angiogenesis but involves circulating endothelial precursors that
may home to ischemic foci and differentiate in situ [21]. Moreover,
Takahashi and colleagues showed that EPCs are mobilized endoge-
nously in response to tissue ischemia or exogenously by GM-CSF
therapy to induce neovascularization of ischemic tissues [22].
Associated with stem cell mobilization, treatment with G-CSFreduced cardiac remodeling and increased cardiac function in pa-
tients with acute myocardial infarction (AMI) [23]. Although these
studies showed the importance of factors in beneﬁting the cardio-
vascular system after ischemic disease, parallel analyses claimed
no improvement in exercise tolerance or myocardial perfusion
after VEGF165 [24] or G-CSF [25] treatment. Therefore, the analysis
of the interplay between organs, cytokines and cells capable of re-
establishing cardiac functionality is a priority in prevision of fur-
ther clinical trials and as an alternative to exogenous cell therapy.
Our laboratory investigated previously whether overexpression
of the propeptide of the insulin-like growth factor family IGF-1Ea
in skeletal muscle leads to recruitment of stem cells from the bone
marrow after cardiotoxin-induced cell damage [4]. Recruitment of
c-Kit and Sca-1 positive cells to the injured muscle was observed
early in the regeneration process suggesting that this speciﬁc pro-
peptide induces the production of local signals to increase prefer-
ential recruitment of circulating stem cells to regenerating tissue.
Furthermore, we recently demonstrated that the IGF-1Ea propep-
tide, expressed in transgenic mouse muscle under cardiac-speciﬁc
post-mitotic control, induces cardiac recovery with decreased scar
formation and lowered inﬂammatory response following myocar-
dial infarction [5]. Although the action of the cardiac IGF-1Ea has
been explored previously, its contribution to stem cell-mediated
repair and angiogenesis remained elusive.
The analysis described in this report shows that supplemental
IGF-1Ea propeptide in the heart promoted increase expression lev-
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cytokine proﬁle correlated with an enrichment of Sca-1/c-Kit posi-
tive SP cells in the bone marrow and with an alternative differen-
tiation fate of local cardiac CD34 positive SP cells in vitro (Fig. 4E).
Considering the pro-migratory role of VEGF-A and MCPs on bone
marrow and peripheral blood progenitor cells [11,17], we hypoth-
esized a corresponding increase of c-Kit and Sca-1 positive cells in
the cardiac tissue. Interestingly, ﬂow cytometric analysis of cardiac
cells did not reveal an enrichment of c-Kit and/or Sca-1 cells in TG
heart compared to WT heart, suggesting that this population is not
mobilized in response to these speciﬁc cytokines or that these spe-
ciﬁc markers diffuse in the circulation where differentiation may
occur before entering the tissue of destination.
Recently, great attention has been dedicated to resident cardiac
stem cells as possible precursors of endothelial cells and cardio-
myocytes. Among the resident stem cells, SP cells received great
interest after the discovery that bone marrow SP showed long-
term multi-lineage reconstitution in lethally irradiated recipients
[9]. The heart contains a side population able to differentiate in
endothelial-like cells in vitro and in vivo [7], indicating that the
potentiality to rebuild the cardiovascular system after injury re-
sides into the cardiac tissue itself. Our data shows that the heart
SP contains mostly CD34 positive cells, which differentiate into
hematopoietic cells and proliferate in response to speciﬁc factors
in vitro. The proliferative response of the CD34 positive SP to EGF
and PDGF is important in prevision of clinical studies aimed to
use autologous stem cells to repair the infarcted heart. Indeed,
expansion of the cardiac stem cell pool may be necessary in cell
therapy analyses to transplant a reasonable number of cells capa-
ble of beneﬁting the heart by paracrine factors and/or differentia-
tion into cardiac cells.
In this study, it is important to underline that the speciﬁc mar-
ker selectivity could be due to a different strain and/or enzymatic
treatment. Furthermore, it is possible that in our conditions we se-
lect a population not residing in the tissue. Indeed, it has been
shown that the sialomucin cell surface marker CD34 plays a role
in leukocyte and HSC trafﬁcking by blocking cell adhesion and
enhancing migration [26], suggesting that the cells present in WT
and TG hearts may be a migratory stem cell pool occurring into
the heart from the blood stream. Further studies are required to
analyze the origin of the CD34 positive cells and whether they con-
tribute to vessels in injured hearts as previously reported [12].
In parallel to the in vitro analysis, we observed that IGF-1Ea over-
expression promoted increased vessel density upon myocardial in-
jury in proximity of the damaged tissue, but not at the distant
areas. These data suggest that IGF-1Ea propeptide contributes indi-
rectly to vessel formation, possibly through the recruitment in the
infarcted area of speciﬁc cells capable of secreting angiogenic factors
(VEGF) and/or rebuilding the loss vasculature. The CD34 positive
cells form tubular-like structure in vitro when primed by IGF-1Ea,
making this stem cell pool a possible contributor to new vessel
formation.
In support of that, we observed that in physiologic conditions
IGF-1Ea overexpression did not correlate with increased new cap-
illaries, despite the signiﬁcant upregulation of the pro-angiogenic
factor VEGF-A. The data may suggest a differential role of VEGF-A
during cardiac development, possibly related to cardiomyocyte
hypertrophy [27,28].
Although the dynamics of IGF-1Ea-mediated cardiac repair are
still under investigation, the data presented here showed that this
speciﬁc propeptide contributes to elicit heart-bone marrow cross-
talk and to modulate bone marrow stem cells response. More-
over, it showed that IGF-1Ea favor side population stem cell to
organize in endothelial-like tubular structure and may be of clin-
ical importance in cell- and gene-mediated therapy in regenera-
tive studies.Acknowledgments
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